Personalized medicine in the postoperative ward
Genetic analysis helped Canadians to choose drugs directly during treatment
According to HealthDay (First Bedside Gene Test Shows Promise), the effectiveness of the technique was evaluated by a group of specialists led by Derek So from the University of Ottawa. A report on their work is published in The Lancet magazine.
Two hundred patients were selected to participate in the study. All participants underwent percutaneous coronary artery surgery for stable angina or acute coronary syndrome. Half of the volunteers were prescribed standard postoperative therapy – 75 milligrams of clopidogrel daily.
The remaining patients underwent rapid analysis to identify different variants of the CYP2C19 gene. In one of the varieties (CYP2C19*2) the gene does not perform its function, clopidogrel is ineffective for carriers of this variant.
According to the results of genetic screening, CYP2C19*2 was detected in 23 participants. In this regard, they were prescribed another drug for the prevention of blood clots (prasugrel). The indicators of platelet activity in the screened patients were within the normal range. After that, a genetic study was conducted in a control group of volunteers. CYP2C19*2 was also detected in 23 patients. At the same time, seven of them had increased platelet activity.
Sou noted that thanks to genetic analysis, cardiologists were able to determine effective tactics for treating patients. At the same time, he added that in order to introduce this technique into clinical practice, it is necessary to conduct extensive research.
Portal "Eternal youth" http://vechnayamolodost.ru
02.04.2012